Vasectomy News and Research

RSS

A vasectomy is a surgical procedure that makes a man sterile, or unable to get a woman pregnant. It is generally considered to be at least as effective as female sterilization and is simpler to perform, safer, and less costly. A vasectomy is done by blocking the tube, called the vas deferens, through which sperm normally pass from each testicle on the way to the seminal vesicle, forming semen.

Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

Celgene International Sàrl announced that clinical data from two investigational studies evaluating the use of REVLIMID (lenalidomide) either with rituximab or following a rituximab-containing regimen in patients with chronic lymphocytic leukaemia were presented at the 52nd American Society of Hematology annual meeting.

6 Dec 2010

First step in development of artificial human testicle

After more than 30 years of unsuccessful efforts by numerous investigators, researchers have now found a way to propagate primary human Sertoli cells in the laboratory. Derived from the testis, it has been difficult to maintain Sertoli cells, the "nurse" cells responsible for overseeing sperm production, outside of the human body.

26 Oct 2010

Less-invasive alternative to vasectomy

Pro-Vas® – the new faster, less-invasive alternative to traditional vasectomy – was featured Thursday in millions of homes and doctors' offices across the nation on "The Doctors" TV show. This nationally syndicated show highlights significant advancements in the world of health and medicine.

13 Sep 2010

Celgene receives Paragraph IV Certification Letter on submission of ANDA for REVLIMID

Celgene Corporation today announced it has received a Paragraph IV Certification Letter advising that Natco Pharma Limited of Hyderabad, India, submitted an Abbreviated New Drug Application to the U.S. Food and Drug Administration. The application requests authorization to manufacture and market generic versions of REVLIMID (lenalidomide) 5, 10, 15 and 25 mg capsules in the United States.

3 Sep 2010

Celgene to enforce REVLIMID intellectual property rights following receipt of Paragraph IV notification letter

Celgene Corporation today announced that information was posted on the FDA Web site indicating that an Abbreviated New Drug Application (ANDA) has been received by the Office of Generic Drugs (OGD) containing a "Paragraph IV" patent certification, for REVLIMID (lenalidomide) 25 mg capsules. Celgene has not yet received the Paragraph IV notification letter identifying the filer.

25 Aug 2010

Celgene receives Japan's MHLW approval for REVLIMID in deletion 5q myelodysplastic syndrome patients

Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. REVLIMID was also approved in June 2010 in combination with dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy.

20 Aug 2010

Conceptus’ Essure procedure effective for permanent birth control

According to the recently released 2006-08 National Survey of Family Growth by the Center for Disease Control, one in four women choose permanent birth control. Conceptus, Inc. wants women to know that its Essure permanent birth control procedure has been gaining in popularity, and is a safe and effective solution used by hundreds of thousands of women worldwide.

4 Aug 2010

Japan's MHLW grants full marketing authorization to REVLIMID

Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare for use in combination with dexamethasone as a treatment for patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy. This marketing authorization represents the first regulatory approval of REVLIMID in Japan.

25 Jun 2010

FDA clears U.Va.'s SpermCheck Fertility at-home test

Couples will soon have a new tool in diagnosing male infertility - without the expense and inconvenience associated with a trip to a specialist's office.

14 Jun 2010

Phase III study of REVLIMID for treating patients with multiple myeloma shows improvement in PFS

Celgene International Sàrl announced that data from the planned second interim analysis (median follow-up of 21 months) of a phase III, randomized, double-blind study of continuous REVLIMID (lenalidomide) for the treatment of elderly patients with newly diagnosed multiple myeloma show improvement in progression-free survival, the primary endpoint of the study.

14 Jun 2010

Clinical data from investigational study of patients with multiple myeloma presented at ASCO

Celgene International Sàrl announced clinical data from an investigational study of patients with multiple myeloma who were younger than 65 years old and received either lenalidomide (REVLIMID), melphalan and prednisone or melphalan plus autologous stem cell transplant (MEL200) following an induction treatment of lenalidomide plus low-dose dexamethasone (Rd) were presented at the American Society of Clinical Oncology annual meeting.

11 Jun 2010

Emerging health care models and approaches discussed at 2010 Health Care Conference

Dr. Sanford J. Siegel, president and CEO of Chesapeake Urology Associates, Maryland, was a featured panelist at the 2010 Health Care Conference for health care community executives, held at the BWI Marriott in Baltimore on June 7, 2010.

10 Jun 2010

Single semen test for clearance following vasectomy

Having to provide repeated semen samples following a vasectomy could soon be a thing of the past, after 96 per cent of men were given the all-clear based on a single test three months after surgery.

8 Jun 2010

Researchers present data from Phase II study of lenalidomide in patients with untreated CLL at ASCO

Celgene International Sàrl today announced that researchers presented data from an investigator-initiated Phase II study of lenalidomide (REVLIMID) in untreated patients with chronic lymphocytic leukemia at the annual meeting of the American Society of Clinical Oncology.

8 Jun 2010

Celgene reports initial data from investigator-initiated study of REVLIMID

Celgene International Sàrl today announced that initial data from an investigator-initiated study of REVLIMID (lenalidomide) plus Rituxan (rituximab) in patients with newly diagnosed indolent B-cell non-Hodgkin's lymphoma (NHL) were presented at the annual meeting of the American Society of Clinical Oncology.

5 Jun 2010

Researchers present clinical outcomes of lenalidomide in patients with large B-cell lymphoma

Celgene International Sàrl today announced researchers at the annual meeting of the American Society of Clinical Oncology presented data from an evaluation of lenalidomide (REVLIMID) in patients with diffuse large B-cell lymphoma either with a germinal center B-cell or non-germinal center B-cell phenotype.

5 Jun 2010

Northwestern Memorial performs robotic assisted vasectomy reversal using da Vinci surgical robot

In 1989 a 29-year-old Michael Schrader had it all: steady job, a wife, and two wonderful children-daughter Courtney and son Cameron. He couldn't envision wanting more-that is, more children. Taking steps to keep his nuclear family intact, he underwent vasectomy- a procedure so routine he was back on the golf course the next afternoon.

28 May 2010

US District Court dismisses all claims and counterclaims in thalidomide patent cases

Celgene Corporation announced that as a result of Barr Laboratories, Inc., withdrawing its Abbreviated New Drug Application (ANDA) for thalidomide with the US Food and Drug Administration, the US District Court for the District of New Jersey has granted the requested dismissal of all claims and counterclaims in the thalidomide patent cases.

27 May 2010

Pro-Vas male contraceptive procedure available to physicians across the U.S.

Pro-Vas is the first male contraceptive procedure, other than condoms or vasectomy, to provide effective affordable birth control for men and it is available to physicians across the United States immediately.

1 Apr 2010

Infertile men are at greater risk for developing prostate cancer: Study

Infertile men are at nearly three times greater risk for developing clinically significant prostate cancer than the average man according to a new study published in the journal, Cancer.

23 Mar 2010